Introduction
============

Genetic alterations of *TP53* are frequent events in tumourigenesis and promote genomic instability, impair apoptosis, and contribute to aberrant self-renewal.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ The spectrum of mutations that occur in *TP53* in human cancers is diverse. Missense mutations that deregulate the DNA-binding domain are common, and prevent or impair the transcriptional regulatory activity of *TP53*.^[@bib3]^ Cytogenetic alterations that delete or disrupt *TP53* have also been reported, as has epigenetic silencing due to methylation of the *TP53* promoter.^[@bib3]^ In both carcinomas and haematopoietic malignancies, *TP53* mutation status has been shown to correlate with prognosis.^[@bib5],\ [@bib6]^ *TP53* is generally considered a tumour-suppressor gene,^[@bib2]^ with inactivation of both copies of the gene seen in many tumours. Paradoxically, several studies have observed accelerated tumourigenesis in *Trp53*^+/−^ mice that develop tumours despite retaining a wild-type copy of *Trp53*.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ Furthermore the analysis of tumours from Li-Fraumeni patients with germline alterations of *TP53,* suggest that a significant proportion may retain a wild-type *TP53* allele.^[@bib11],\ [@bib12],\ [@bib13]^ Threshold levels of P53 are required for processes such as suppression of apoptosis or induction of cell-cycle arrest.^[@bib14]^ In the context of *TP53* heterozygosity it is possible that transcriptional silencing of the wild-type *TP53* allele by mechanisms such as promoter methylation, altered *cis-*regulation of the gene that decreases transcription from the wild-type *TP53* allele, or post-translational modification of P53, decreases *TP53* function to a level such that tumourigenesis can occur. In this paper we set out to identify, which somatically mutated genes can contribute to tumour formation in the context of *Trp53* heterozygosity. To do this we used mice heterozygous for *Trp53* (as well as *Trp53* wild type and null controls) to genetically dissect this phenomenon focusing on leukaemogenesis as a model system. This analysis allowed us to identify nine loci that are potentially associated with tumour formation in the context of *Trp53* heterozygosity. We show that the Jun dimerization protein 2 (*Jdp2)* is a site frequently targeted by transposon insertion events leading to upregulated *Jdp2* expression and a decrease in *Trp53* expression levels. Further we illustrate that *Jdp2* regulates the *Trp53* promoter via an atypical AP-1 binding site. This study is the first to identify a genetic mechanism for tumour formation in the context of *Trp53* heterozygosity.

Results and discussion
======================

Mouse lines carrying the mutant *Trp53* allele, *Trp53*^*Tyr*^, which are null for *Trp53*,^[@bib15]^ the *SB* (*Sleeping Beauty*) transposon array, *T2/Onc,*^[@bib16]^ and the *SB* transposase allele, *Rosa26*^*SB11*^ (see Dupuy *et al.*^[@bib17]^) were intercrossed to generate mice that were homozygous, heterozygous or wild type for the *Trp53*^*Tyr*^ allele (hereafter referred to as *Trp53*^−/−^*, Trp53*^+/−^ or *Trp53*^+/+^ mice, respectively) with or without *SB* transposition occurring (that is, on a *T2/Onc*^+/*Tg*^ *Rosa26*^+/*SB11*^ or *T2/Onc*^+/+^, *Rosa26*^+/*SB11*^ background, respectively). These mice were aged until they became moribund, and, as expected, *SB* transposition significantly accelerated tumour latency in mice of all genotypes ([Figure 1a](#fig1){ref-type="fig"}). The predominant tumour type of all genotypes was a widely disseminated CD3^+^ T-cell lymphoma ([Figures 1b and c](#fig1){ref-type="fig"}). A number of solid tumours, mainly undifferentiated sarcomas, were also observed, but only in *Trp53*^+/−^ or *Trp53*^−/−^ mice ([Figures 1b and c](#fig1){ref-type="fig"}).

Genomic DNA from 36 *Trp53*^+/+^, 116 *Trp53*^+/−^ and 9 *Trp53*^−/−^ SB-induced leukaemic/lymphomic tissues (typically spleen, thymus or lymph node) was extracted and subjected to a previously described linker-mediated PCR approach^[@bib18]^ to amplify barcoded genomic fragments containing transposon--genome junction sequences. These products were then pooled and sequenced on the 454 platform, from which we generated 487 586 uniquely mapped sequence reads (approximately 3000 per tumour). After merging overlapping reads originating from the same sample and removing any on chromosome 1 (because SB transposons frequently reintegrate into regions adjacent to the donor locus---a phenomenon known as 'local hopping\'^[@bib16]^), we obtained 7538 (*Trp53*^+/+^), 21 975 (*Trp53*^+/−^) and 1829 (*Trp53*^−/−^) unique, non-redundant insertion sites (for the respective tumour genotypes indicated in brackets). Using a previously described Gaussian Kernel Convolution statistical method for determining common insertion sites (CISs),^[@bib19],\ [@bib20]^ we identified 42, 63 and 9 CIS[S]{.smallcaps} in *Trp53*^+/+^, *Trp53*^+/−^ and *Trp53*^−/−^ tumours, respectively, (*P*\<0.05 on a chromosome-adjusted scale; [Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Many of these genes have been previously implicated in the pathogenesis of T-cell lymphomagenesis/leukaemogenesis, including *NOTCH1*, *PTEN* and *IKZF1* (reviewed in Demarest *et al.*^[@bib21]^). There were 12 CIS genes in common between the *Trp53*^+/+^ and *Trp53*^+/−^ tumours, specifically *Mecom* (*Mds1* and *Evi1* complex locus), *Myb*, *Notch1*, *Stat5b*, *Erg*, *Ikzf1*, *Raf1*, *Rasgrp1*, *Zmiz1*, *Pten*, *AB041803* and *Il2rb*. Given that eight of these genes have also been identified as CIS[S]{.smallcaps} in leukaemias/lymphomas from *T2/Onc;Rosa26-SB11* mice on a wild-type background (*Myb*, *Notch1*, *Erg*, *Ikzf1*, *Rasgrp1*, *Zmiz1*, *Pten* and *AB041803*),^[@bib22]^ they likely represent genes involved in lymphomagenesis/leukemogenesis in general, and do not contribute to promotion of tumourigenesis in the context of *Trp53* heterozygosity.

A CIS gene that was found in the *Trp53*^+/−^ and *Trp53*^−/−^ tumours, but not *Trp53*^+/+^ tumours, was *Rapgef6*. The Rap1 guanine nucleotide exchange factor RAPGEF6 (also known as PDZGEF2) has a critical role in the maturation of adherens junctions.^[@bib23]^ Although no immediate role for RAPGEF6 in tumourigenesis is evident, it has been shown to form protein complexes that result in the activation of Rap1A and control of cell adhesion/migration.^[@bib24],\ [@bib25]^ Interestingly, apart from *Rapgef6*, the CIS genes found in the *Trp53*^−/−^ tumours were not found in tumours of the other genotypes. These included genes *Usp42* (ubiquitin specific peptidase 42) and *Wdr33* (WD repeat-containing protein 33). Although little is known about *Wdr33* gene, *Usp42* gene has been recently identified as a fusion partner of *RUNX1* in three cases of myeloid neoplasia, and the associated upregulated expression of USP42 suggests a role of this deubiquitinating enzyme in the pathogenesis of this leukaemia.^[@bib26]^

There were also four CIS[S]{.smallcaps} that were found to co-occur in tumours ([Figure 2](#fig2){ref-type="fig"}), specifically *Notch1* and *Pten*, *Notch1* and *Ikzf1*, *Pten* and *Ikzf1* and *Pten* and *Akt2* in *Trp53*^+/−^ tumours. These genes have all been previously implicated in the pathogenesis of T-ALL.^[@bib21],\ [@bib27]^ Our results are in keeping with the literature, as there is evidence for genetic co-operation of these genes in development of T-ALL. For example, loss of *Ikzf1*, a direct repressor of Notch target genes, and suppression of p53-mediated apoptosis are essential for development of T-ALL and PTEN inactivation can compensate for some Notch-mediated processes in T-ALL.^[@bib21]^ In addition, retroviral insertional mutagenesis recently identified *Ikzf1*, *Kras*^*G12D*^ and *Notch1* as a novel genetic pathway in T-lineage leukaemogenesis.^[@bib28]^

Quantitative PCR was performed on all tumours from *Trp53*^+/−^ mice to identify those that had retained a wild-type copy of *Trp53* and those that carried two copies of the targeted *Trp53*^*Tyr*^ allele (presumably having lost the wild-type allele by mitotic recombination; [Figure 3a](#fig3){ref-type="fig"}). From the 111 *Trp53*^+/−^ tumours analysed, we identified 40 that had retained a wild-type *Trp53* allele (defined as having a normalised wild-type allele content of \>0.28 and a *Trp53*^*Ty*r^ allele content of \<0.7) and 27 tumours that carried two targeted *Trp53*^*Tyr*^ alleles and no wild-type allele signal (defined as having a normalised wild-type allele content of \<0.1 and a *Trp53*^*Tyr*^ allele content of \>0.8). To determine if there were any somatic mutations in the intact wild-type copy of *Trp53*, genomic DNA from all 111 *Trp53*^+/−^ tumours (as well as some tail samples to facilitate the identification of somatic mutations) underwent *Trp53* sequencing on the Illumina platform (Illumina, San Diego, CA, USA) to scan for point mutations (using the primers shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Paired-end sequencing of PCR amplified fragments was followed by base-calling with SAMTOOLS mpileup,^[@bib29]^ which identified three possible mutations, specifically MMU11:69400422 (T-C), MMU11:69403089 (G-A) and MMU11:69403110 (G-A) in single tumours. All other tumours appeared to have retained the wild-type *Trp53* allele. A further two sequence changes at MMU11:69401065 and MMU11:69401996 were discovered in 22 and 44 of the samples, respectively, and are therefore likely to be germline variants (as these mice were on a mixed C57BL/6J-129Sv background and the sequencing data was compared with the C57BL/6J reference genome). These data suggest point mutations of the wild-type *Trp53* are infrequent in our model.

Taking the insertion sites found in tumours from *Trp53*^+/−^ mice, we performed CIS analysis in two ways. First, the tumours were divided into two groups: those that had either retained a wild-type copy of *Trp53* or those that had lost the wild-type copy to identify the CIS[S]{.smallcaps} that were unique and common to each group ([Figure 3b](#fig3){ref-type="fig"}). We found a set of nine CIS loci enriched in *Trp53*^+/−^ mice that developed tumours despite retaining a wild-type copy of the gene, including *AB041803*, *Akt2*, *Eras*, *Ikzf1*, *Jdp2*, *Myb*, *Rapgef6* and two intergenic regions. Second, we pooled the insertion sites from both groups together and then distinguished genotype-specific CIS[S]{.smallcaps} using a *P*-value generated by Fisher\'s Exact test analysis.^[@bib30]^ Using this more 'stringent\' method of CIS calling, we identified two CIS[S]{.smallcaps} that were 'enriched\' in *Trp53*^+/−^ tumours that had retained a wild-type copy of *Trp53*, specifically *AB041803* and *Jdp2*. Little is known about *AB041803* and as yet no role in tumourigenesis is evident. In addition, it was also found to be a CIS in leukaemia/lymphoma of wild-type mice ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).^[@bib22]^ Thus we focused on *Jdp2*.

Transcription factor JDP2 (also known as JUNDM2) is an AP-1 repressor protein^[@bib31]^ that has a paradoxical role in tumour formation. Overexpression of *Jdp2* has been shown to potentiate hepatocellular carcinoma in mice^[@bib32]^ and retroviral insertions predicted to activate the gene have been reported in mouse lymphoma models.^[@bib33],\ [@bib34]^ In contrast, downregulation of *JDP2* has been associated with a poor prognosis in pancreatic cancer.^[@bib35]^ Loss of *Jdp2* has also been associated with resistance to replicative senescence,^[@bib36],\ [@bib37]^ and *Jdp2* expression has been shown to suppress cell-cycle progression by downregulation of cyclin-A2.^[@bib38]^ However, hypomethylation of the *Jdp2* promoter or upregulation of *Jdp2* expression in common myeloid progenitors and in granulocyte-macrophage progenitors has led to suggestions that it functions as a regulator of myelopoiesis.^[@bib39]^ Here, we find that transposon insertions in the *Jdp2* promoter occur exclusively in tumours from *Trp53*^+/−^ mice that retain a wild-type allele of *Trp53*. These insertions clustered in the promoter of *Jdp2* ([Figure 3c](#fig3){ref-type="fig"}) and were mostly orientated so that the transposon was inserted in the same transcriptional orientation as the gene, suggesting that these insertions were functioning to drive overexpression (with a single insertion orientated on the reverse strand relative to the gene, which may represent an enhancer insertion^[@bib40]^). RT--PCR on RNA from these tumours showed splicing of the T2Onc transposon splice donor site directly onto *Jdp2* exons 2 and/or 3 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Indeed insertions in this exact location have been shown to activate *Jdp2* expression,^[@bib34]^ and consistent with this, qPCR on RNA from tumours containing insertions in *Jdp2* showed a trend towards having higher expression levels of *Jdp2* and lower expression levels of *Trp53*, relative to *Trp53*^+/−^ tumours with no insertions in *Jdp2* (randomly selected from mice on this study that had not lost the *Trp53* allele by mitotic recombination; [Figure 3d](#fig3){ref-type="fig"}).

Co-transfection of *JDP2* cDNA in an overexpression vector with a mouse *Trp53* proximal promoter construct in murine NIH3T3 ([Figure 3e](#fig3){ref-type="fig"}) and human HEK293T cells (data not shown) resulted in significant repression of *Trp53* promoter activity, confirming that overexpression of *JDP2* functions directly on the *Trp53* promoter to repress *Trp53* expression. The ability of JDP2 to repress transcription of the *p53* promoter is reported to occur via its binding to an atypical AP-1 site, termed the PF-1 site, in the *p53* promoter.^[@bib41]^ When we mutated (deleted) this binding site in the proximal *Trp53* promoter, this completely abrogated the suppressive effects of *JDP2* ([Figure 3e](#fig3){ref-type="fig"}), confirming that overexpression of *JDP2* mediates repression of *Trp53* through the PF-1 site in the proximal promoter. Furthermore, overexpression of *JDP2* in HEK293T cells was shown to repress endogenous *TP53* expression ([Figure 3f](#fig3){ref-type="fig"}).

In conclusion, we show that overexpression of *Jdp2* in tumours that are heterozygous for *Trp53* precludes the need for loss of the wild-type allele of *Trp53* during the process of leukaemogenesis*. Jdp2* overexpression is the first genetic mechanism that has been identified as being responsible for tumour formation in the context of *Trp53* heterozygosity.
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![Loss of *Trp53* promotes tumourigenesis. (**a**) Kaplan--Meier curves showing the tumour latency in *Trp53*^+/+^, *Trp53*^+/−^ and *Trp53*^−/−^ mice on a transposon 'jumping\' background (that is, *T2/Onc*^+/*Tg*^ *Rosa*^+/*SB11*^ solid lines) and 'non-jumping\' control background (that is, *T2Onc*^+/+^; *Rosa26*^+/*SB11*^ dashed lines). Curve comparison using the log-rank (Mantel--Cox) test: *P*\<0.0001 for *Trp53*^+/+^ vs *Trp53*^+/−^ vs *Trp53*^−/−^ mice on a 'jumping\' background. (**b**) Categorisation of the malignancies developed by the *Trp53*^+/+^, *Trp53*^+/−^ and *Trp53*^−/−^ mice on a 'jumping\' background according to the tumour type. Several mice had multiple tumour types. Numbers in brackets represent the percentage of mice developing a specific tumour type as a proportion of the genotype. (**c**) Representative photomicrographs of formalin-fixed, hematoxylin- and eosin-stained sections of (i) thymic lymphoma, (ii) splenic lymphoma, (iii) undifferentiated sarcoma and (iv) osteosarcoma. Representative photomicrographs of immunohistochemically-stained liver sections infiltrated by lymphomas of (v) B-cell origin (CD45R^+^) or (vi) T-cell origin (CD3^+^). Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections that had undergone antigen retrieval (microwaving in high pH citrate buffer for 3 × 5 min) using rabbit anti-human polyclonal CD3 antibody (Dako, Ely, UK) and rat anti-mouse/human monoclonal B220/CD45R antibody (BD Biosciences, Oxford, UK). The immunohistochemical signal was detected using a secondary biotinylated goat anti-rabbit or anti-rat antibody (Vector Laboratories, Burlingame, CA, USA), using the Vectorstain Elite ABC kit (Vector Laboratories) according to the manufacturer\'s instructions. All sections shown are representative and images are at × 400 magnification.](onc201256f1){#fig1}

![Analysis of common insertion sites. A Circos plot showing the common insertion sites (CIS[S]{.smallcaps}) called in tumours from *Trp53*^+/+^ (black), *Trp53*^+/−^ (blue) and *Trp53*^−/−^ (red) mice. Lines crossing the circle indicate statistically significant co-occurring mutations with the thickness of the line indicating the level of significance. All tumour DNA was extracted using GenePure kits (Qiagen, Sussex, UK) and transposon insertion site sequences were generated on the 454 platform (Roche, West Sussex, UK), as described previously.^[@bib30]^ Processing of 454 reads, identification of insertion sites, and the Gaussian Kernel Convolution statistical methods used to identify CIS[S]{.smallcaps} have been described previously.^[@bib19],\ [@bib20]^ The *P*-value for each CIS was calculated using an adjusted-by-genome cutoff of *P*\<0.05. A complete list of the CIS[S]{.smallcaps} is given in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.](onc201256f2){#fig2}

![Identification of driver mutations associated with loss of *Trp53* by mitotic recombination or with the retention of a wild-type copy of *Trp53.* (**a**) SYBR Green quantitative real-time PCR (ABI, Carlsbad, CA, USA) was performed on tumour genomic DNA to quantify the relative proportions of *Trp53* wild-type and *Trp53*^*Tyr*^ alleles in genomic DNA extracted from the leukaemias/lymphomas and data were normalised to the single-copy genes *β-Actin* and *Gapdh* (primers are detailed in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Red triangles represent tumours from *Trp53*^−/−^ mice, blue squares represent tumours from *Trp53*^+/−^ mice and black circles represent tumours from *Trp53*^+/+^ mice. Of the tumours from *Trp53*^+/−^ mice: open squares are those that have retained a wild-type copy of *Trp53*, closed dark blue squares are those that have lost the wild-type *Trp53* allele by mitotic recombination (MR) and closed light blue squares are those with a mixture of *Trp53*^+/−^ and *Trp53*^−/−^ cells and thus were excluded from further analyses. (**b**). Common insertion sites (CISs) were identified in tumours from *Trp53*^+/−^ mice that had retained a wild-type copy of *Trp53* (dotted blue circle) and those that had lost the wild-type copy (solid blue circle) as described previously.^[@bib19],\ [@bib20]^ CIS[S]{.smallcaps} were called using a genome wide cut-off of *P*\<0.05. Asterisk indicates the CIS was also found in the other genotype/circle, but below the *P*\<0.05 cut-off. Double asterisk indicates the CIS[S]{.smallcaps} were in intergenic regions (that is, not located within ±150K base pairs of a gene and were given the label 'CIS\' followed by the chromosome and the peak location of the Gaussian kernel; there were two regions for 'tumours retaining a wild-type copy of *Trp53\'*: CIS7:37317163_15k and CIS5:75854217_15k, and one for 'tumours without a wild-type copy of *Trp53\'*: CIS7:37322632_15k) (**c**). Location and orientation of the transposon insertions (blue triangles) associated with the *Jdp2* CIS (the exons of *Jdp2* are represented as boxes). One tumour was found to harbour multiple independent transposon insertion events (indicated with dotted lines). (**d**). Quantitative PCR (qPCR) was performed on five tumours containing insertions in *Jdp2* and nine randomly selected *Trp53*^+/−^ T-cell tumours (without insertions in *Jdp2*). RNA was extracted using the RNeasy Minikit (Qiagen), DNAse-treated (Turbo DNase, Ambion, Warrington, UK) and reverse transcribed (RNA to cDNA EcoDry Random Hexamers, Clontech, Mountain View, CA, USA) according to the manufacturer\'s instructions. Quantitative PCR was performed in triplicate using SYBR Green PCR MasterMix (Applied Biosystems, Carlsbad, CA, USA) and the CT for *Trp53* and *Jdp2* were normalized to the 'control\' (average of five housekeeping genes: *Gapdh*, *β-Actin*, *Hprt1*, *Rpl32* and *Rpl13a*) using the 2^--CT^ method.^[@bib42]^ Primers used for qPCR are given in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}. (**e**). Transient overexpression of *JDP2* in NIH3T3 cells resulted in a significant repression of *Trp53* proximal promoter activity. The 375 bp mouse *Trp53* proximal promoter (*Trp53-Luc*) was PCR amplified from tail genomic DNA (using primers: F: 5′-AAAAAAAAGGTACCGGTCCACTTACGATAAAAAC-3′ and R: 5′-AAAAAAAAAAGATCTGGTCCCAATGAACTGAAGCT-3′) and cloned into the pGL3-BASIC vector (Promega, Southhampton, UK). The mutated mouse *Trp53* proximal promoter in which the 7 bp PF-1 site (5′-TGACTCT-3′) was removed (*mutTrp53-Luc*) was synthesized (GeneArt-Invitrogen, Paisley, UK) and cloned into the pGL3-BASIC vector. A full-length human *JDP2* cDNA was obtained from Origene (Rockville, MD, USA). NIH3T3 cells grown in 96-well plates were transfected with (i) either 100 ng *Trp53-Luc* (black lines) or *mutTrp53-Luc* (grey lines), (ii) 20 ng pRL-SV40 (an internal control reporter; Promega) and (iii) either 50 ng *JDP2* cDNA or empty vector according to the manufacturer\'s instructions (Lipofectamine 2000; Invitrogen). Firefly and Renilla luciferase were measured 50 h later using the Dual-Luciferase Reporter Assay System according to the manufacturer\'s instructions (Promega). The firefly light units were normalised to the Renilla light units. All data were normalised to the average value of the 'control\' transfection (*Luc* vector plus empty vector) and were presented as fold-change relative to the control. Experiments were performed in triplicate on at least three independent occasions and the data analysed by two-tailed Student\'s *t*-test. (**f**). Transient overexpression of *JDP2* in HEK293T cells represses *TRP53* expression. HEK293T cells (Gryphon Eco, Allele Biotechnology, San Diego, CA, USA) were seeded in 12-well plates and transfected with 2 μg Myc-DDK-tagged ORF clone of *JDP2* (pCMV6Entry; Origene) or empty vector, according to the manufacturers\' instructions (Lipofectamine 2000, Invitrogen). Experiments were performed in triplicate. RNA was extracted 48 h post-transfection and reverse transcribed as described above. Quantitative PCR was performed in triplicate using SYBR Green PCR MasterMix (Applied Biosystems) and the CT for *TP53* and *JDP2* were normalized as described above. Primers used for qPCR are given in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}.](onc201256f3){#fig3}
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